Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of prescription medicines and vaccines. The company operates within the pharmaceuticals and biotechnology industries, with a focus on therapeutic areas including oncology, immunology, cardiology, rare diseases, vaccines, and internal medicine. Pfizer’s revenue is primarily driven by branded biopharmaceutical products protected by intellectual property and regulatory exclusivity, alongside lifecycle management and global commercialization capabilities.
Founded in 1849 in Brooklyn, New York, Pfizer began as a chemical manufacturing company and evolved into one of the world’s largest research-based pharmaceutical firms. Over time, it expanded through sustained internal R&D investment and major acquisitions, including Warner-Lambert, Wyeth, and Seagen, shaping its current portfolio and scale. Pfizer is recognized for its global manufacturing footprint, late-stage development expertise, and ability to rapidly scale production, notably demonstrated during the COVID‑19 pandemic.
Business Operations
Pfizer organizes its operations primarily into two reportable business segments: Biopharma and Pfizer CentreOne. Biopharma is the core revenue-generating segment, encompassing Pfizer’s portfolio of innovative medicines and vaccines across multiple therapeutic categories. Revenue is generated through direct sales to hospitals, wholesalers, governments, and healthcare providers worldwide. Pfizer CentreOne provides contract manufacturing and active pharmaceutical ingredient production for both internal use and external partners.
The company maintains extensive R&D, manufacturing, and commercial infrastructure across domestic and international markets. Pfizer controls proprietary drug platforms, biologics manufacturing technologies, and global supply chain assets. Key subsidiaries include Pfizer Manufacturing LLC and Pfizer Investment Enterprises Pte. Ltd., while partnerships include strategic collaborations with biotechnology firms and academic institutions. Pfizer has also engaged in co-development and commercialization agreements to expand its pipeline and geographic reach.
Strategic Position & Investments
Pfizer’s strategic direction emphasizes innovation-driven growth, disciplined capital allocation, and portfolio optimization. The company prioritizes investment in high-growth therapeutic areas such as oncology, vaccines, and rare diseases, while managing patent expirations through pipeline development and acquisitions. A major strategic move was the acquisition of Seagen Inc., significantly expanding Pfizer’s oncology portfolio and antibody-drug conjugate capabilities.
In addition to acquisitions, Pfizer invests heavily in internal R&D and selective external partnerships to access emerging technologies, including mRNA platforms, gene therapies, and precision medicine. The company also maintains a venture capital presence through Pfizer Ventures, which invests in early- and mid-stage biotechnology companies aligned with Pfizer’s strategic priorities.
Geographic Footprint
Pfizer is headquartered in New York, United States, and operates globally with a presence across North America, Europe, Asia-Pacific, Latin America, and Africa. The company markets its products in more than 125 countries and maintains manufacturing and research facilities across multiple continents, supporting both local and global supply needs.
International markets contribute a substantial portion of Pfizer’s revenue, with significant operations in the United States, Western Europe, Japan, and emerging markets. Pfizer’s global footprint enables diversified revenue streams, regulatory risk mitigation, and access to varied healthcare systems and patient populations.
Leadership & Governance
Pfizer is led by an executive team with extensive experience in pharmaceuticals, science, and global operations. The company emphasizes a leadership philosophy centered on science-driven decision-making, ethical governance, and long-term value creation for patients and shareholders. Oversight is provided by an independent board of directors, with governance practices aligned to U.S. public company standards.
Key executives include:
- Albert Bourla – Chairman and Chief Executive Officer
- David Denton – Chief Financial Officer
- Angela Hwang – Chief Commercial Officer
- Mikael Dolsten – Chief Scientific Officer and President, Worldwide Research, Development and Medical
- Aamir Malik – Chief Business Innovation Officer
- Payal Sahni Becher – Chief People Experience Officer